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Abstract
This article is part of a series written for people responsible for making decisions about health policies and
programmes and for those who support these decision makers.
Differences between health systems may often result in a policy or programme option that is used
in one setting not being feasible or acceptable in another. Or these differences may result in an
option not working in the same way in another setting, or even achieving different impacts in
another setting. A key challenge that policymakers and those supporting them must face is
therefore the need to understand whether research evidence about an option can be applied to
their setting. Systematic reviews make this task easier by summarising the evidence from studies
conducted in a variety of different settings. Many systematic reviews, however, do not provide
adequate descriptions of the features of the actual settings in which the original studies were
conducted. In this article, we suggest questions to guide those assessing the applicability of the
findings of a systematic review to a specific setting. These are: 1. Were the studies included in a
systematic review conducted in the same setting or were the findings consistent across settings or
time periods? 2. Are there important differences in on-the-ground realities and constraints that
might substantially alter the feasibility and acceptability of an option? 3. Are there important
differences in health system arrangements that may mean an option could not work in the same
way? 4. Are there important differences in the baseline conditions that might yield different
absolute effects even if the relative effectiveness was the same? 5. What insights can be drawn about
options, implementation, and monitoring and evaluation? Even if there are reasonable grounds for
concluding that the impacts of an option might differ in a specific setting, insights can almost always
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be drawn from a systematic review about possible options, as well as approaches to the
implementation of options and to monitoring and evaluation.
About STP
This article is part of a series written for people responsible for
making decisions about health policies and programmes and for
those who support these decision makers. The series is intended
to help such people ensure that their decisions are well-informed
by the best available research evidence. The SUPPORT tools
and the ways in which they can be used are described in more
detail in the Introduction to this series [1]. A glossary for the
entire series is attached to each article (see Additional File 1).
Links to Spanish, Portuguese, French and Chinese translations
of this series can be found on the SUPPORT website http://
www.support-collaboration.org.  Feedback about how to
improve the tools in this series is welcome and should be sent to:
STP@nokc.no.
Scenarios
Scenario 1: You are a senior civil servant and will be submitting
a brief report to the Minister regarding the evidence to support
an option that has been provisionally selected to address a high-
priority problem. You are concerned about whether the findings
of a relevant high-quality systematic review that was used to
make the selection are likely to be applicable to your specific set-
ting, and you want to ensure that this issue has been assessed
by your staff.
Scenario 2: You work in the Ministry of Health and are prepar-
ing a brief report about an option that is being considered to
address a high-priority problem. All that you have been told is
that the report should summarise the findings from the most rel-
evant high-quality systematic review and assess the applicability
of the findings to your setting.
Scenario 3: You work in an independent unit that supports the
Ministry of Health in its use of evidence in policymaking. You
are preparing a detailed research report for the Ministry of
Health about what is known and not known about an option to
address a high-priority problem. You have been told that policy-
makers have found a particular systematic review to be persua-
sive but you want guidance on how to assess whether the
findings of the review are applicable to your setting.
Background
For policymakers (Scenario 1), this article suggests a
number of questions that they might ask their staff to con-
sider when preparing a brief report about a systematic
review that could form the basis for selecting an option
and communicating the rationale for the selection. For
those who support policymakers (Scenarios 2 and 3), this
article suggests a number of questions to guide the assess-
ment of the applicability of the findings of a systematic
review to a specific setting. This article is the third of four
articles in this series about finding and assessing system-
atic reviews to inform policymaking (see also Articles 7, 8
and 10 [2-4]). Figure 1 outlines the steps involved in find-
ing and assessing systematic reviews to inform policymak-
ing.
Commonalities in human biology mean that a clinical
procedure or drug will often work the same way in differ-
ent patients. However, this is not always the case and
questions have thus been developed to help healthcare
providers to assess the applicability of research evidence
to their patients [5]. Differences between health systems
often mean that a policy or programme option being used
in one setting may not be feasible or acceptable in another
setting. These differences may also mean that an option
may not work the same way in another setting or that it
may achieve different impacts in another setting [6,7]. For
example, the implementation of user fees failed to achieve
consistent positive impacts in many sub-Saharan African
countries compared to countries in other regions. In part,
this was due to a number of contextual considerations,
such as people's lack of familiarity with paying for public
health services [8]. A key challenge that policymakers and
those supporting them must face, therefore, is to deter-
mine whether research evidence about the impacts of an
option are applicable to their setting.
Systematic reviews make this task easier by offering a sin-
gle summary of studies from different settings. The word
'settings', in this instance, refers to political/country juris-
dictions (e.g. Canada or Cameroon, or their constituent
provinces). But settings can also include sectors (e.g. pri-
mary care or hospital care), and locales  (e.g. urban or
rural). Systematic reviews can also assist with the process
of making judgements about the applicability of the evi-
dence to specific settings by providing a framework and,
when available, research evidence that can be used to
identify those factors that are essential for an option to
work - or that might modify its impacts. A systematic
review of pharmaceutical policies (i.e. referencing pricing,
other pricing, and purchasing polices for drugs), for exam-
ple, provided a summary of the factors that could influ-
ence the impacts of reference pricing, as well as the
rationale for each factor [9]. These factors included the
equivalence of the drug, incentives, exemptions, drug
availability, price levels, and electronic information sys-
tems.Health Research Policy and Systems 2009, 7(Suppl 1):S9 http://www.health-policy-systems.com/content/7/S1/S9
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Unfortunately, many systematic reviews do not do the fol-
lowing:
• Highlight the features of the settings in which studies
were conducted, particularly those features that might
modify the impacts of an option
￿ Provide a framework for identifying potential modifying
factors, or
￿ Provide research evidence about modifying factors
In these cases, policy analytic articles or narrative reviews
may provide more helpful frameworks that could be used
to inform judgements about the applicability of the evi-
dence in a systematic review.
A framework for understanding corruption in the health
sector and its determinants, for example, highlighted how
health system arrangements (e.g. governance arrange-
ments that limit monopolies, require transparency, and
support enforcement) and other factors, influenced
'opportunities' and 'pressure' to abuse, as well as the
rationalisation for abuse, and how this in turn influenced
the abuse of power for private gain [10]. But, ideally, a sys-
tematic review about the impacts of anti-corruption
efforts would also have described the relevant health sys-
tem arrangements in the settings where the studies were
conducted. Those features that might influence opportu-
nities and pressure to abuse and the rationalisation of
such behaviour, would be of particular interest as they
would allow the reader to link the determinants identified
by the framework with the findings presented in the
review.
Applicability considerations are equally, if not more
important, for other types of systematic reviews. Reviews
of administrative database studies and of community sur-
veys can help to place problems in comparative perspec-
tive, for example, and reviews of observational studies can
help to characterise an option's likely harms. Reviews of
qualitative studies can assist in understanding the mean-
ings that individuals or groups assign to particular prob-
lems, how and why particular options work, and
Finding and assessing systematic reviews to inform policymaking Figure 1
Finding and assessing systematic reviews to inform policymaking.
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stakeholder views about experiences with particular
options. What follows in this article, however, is more
focused on systematic reviews about the impacts of an
option. That said, this may provide some help in assessing
the local applicability of the findings of reviews of obser-
vational studies about harms, be supported by reviews
about how and why particular options work, and give
some insights into how to approach local applicability
assessments of other types of reviews.
Questions to consider
The following five questions can guide how to assess
whether the findings from a systematic review are applica-
ble to a specific setting.
1. Were the studies included in a systematic review con-
ducted in the same setting or were the findings consistent
across settings or time periods?
2. Are there important differences in on-the-ground reali-
ties and constraints that might substantially alter the fea-
sibility and acceptability of an option?
3. Are there important differences in health system
arrangements that may mean an option could not work in
the same way?
4. Are there important differences in the baseline condi-
tions that might yield different absolute effects even if the
relative effectiveness was the same?
5. What insights can be drawn about options, implemen-
tation, and monitoring and evaluation?
1. Were the studies included in a systematic review 
conducted in the same setting or were the findings 
consistent across settings or time periods?
If the studies included in a systematic review were con-
ducted in the same setting where policymakers are based,
or else in very similar settings, there may be little reason to
be concerned about the applicability of the findings. Sim-
ilarly, if the findings have been shown to be consistent
across settings or time periods then similar impacts might
be expected. On-the-ground realities and constraints,
health system arrangements and baseline conditions, are
likely to differ across settings and change over time, so
consistent findings in these circumstances are likely to
mean the findings are broadly applicable. (These three
issues are the focus of the next three questions that follow
in this section.)
The following information in systematic reviews can be
used by policymakers to inform judgements related to
such issues:
￿ Information about the settings of studies and specifica-
tions regarding the time periods over which the studies
were conducted. This can typically be found in a section
of the review entitled 'Characteristics of included studies'
(or similar)
￿ Information about the consistency of findings can typi-
cally be found in the review abstract or in its 'Results' sec-
tion
When information about settings and time periods is lack-
ing in a systematic review, policymakers and those who
support them could contact the authors of the review to
see if they have this information and did identify key local
applicability considerations. If this contact yields little of
value, they could then retrieve the original studies to
locate this information if the issue is of sufficiently high
priority, and if resources and time allow. A potential ben-
efit of the direct contact with review authors is that it may
encourage them to give attention to information needed
for local applicability assessments and considerations in
future reviews.
Research comparing mortality rates in not-for-profit hos-
pitals with mortality rates in for-profit hospitals provides
an example of how such data can be used [11]. This
research had been conducted over several decades in the
United States during which the health system had
changed dramatically. The research demonstrated remark-
able consistency over time in the significant survival
advantage of being treated in not-for-profit hospitals.
Based on these findings, a policymaker from Canada
might then conclude that a similarly consistent finding
would be seen in a Canadian setting. And this conclusion
might lead them to avoid the introduction of for-profit
hospitals into the current system which consists only of
not-for-profit hospitals (or at least to avoid using health
benefits as a justification for doing so).
2. Are there important differences in on-the-ground 
realities and constraints that might substantially alter the 
feasibility and acceptability of an option?
If the studies included in a systematic review were con-
ducted in settings with largely similar resource and capac-
ity constraints to the setting where the findings may be
applied,  and  largely similar perspectives and political
influence amongst health system stakeholders, policy-
makers might reasonably expect that an option would be
both feasible and acceptable in their own setting. How-
ever, policymakers will rarely be able to find information
about resource and capacity constraints and stakeholder
influence in a systematic review. Instead, they will find a
description of the option that was studied. Typically they
will be sufficiently familiar with the resources, capacity,
and stakeholder influence in their own setting to enableHealth Research Policy and Systems 2009, 7(Suppl 1):S9 http://www.health-policy-systems.com/content/7/S1/S9
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them to judge the feasibility and acceptability of the
option.
Policymakers in a setting with very significant resource
and capacity constraints will have to think twice about the
feasibility of an option [12]. Some settings, for example,
may face a shortage of nurse practitioners and therefore
any option requiring a significant role for this category of
healthcare provider might not be feasible in the short-
term [13]. Similarly, some settings have such limited
financial resources that an option shown to have signifi-
cant impacts, such as artemisinin-based combination
therapies (ACT) to treat malaria, might not be considered
feasible on a large scale without significant donor support
[14]. Some health systems may be too overstretched to
accommodate an increase in demand that may accom-
pany the introduction of conditional cash transfers (i.e.
the provision of money to households on the condition
that they comply with certain health and healthcare-seek-
ing behaviours) [14,15]. Or settings may lack the capacity
within governments or among managers, healthcare pro-
viders and consumers (i.e. healthcare recipients and citi-
zens) to support the widespread use of a particular option.
Audit and feedback (i.e. the provision of healthcare pro-
viders with data about their performance), for example,
might not be feasible in settings where routinely collected
data are unreliable.
In a setting in which stakeholders are opposed to an
option and have significant influence on practice and pol-
icy, policymakers may have to assess the likely acceptabil-
ity of an option particularly carefully. Healthcare provider
associations, such as nursing associations, for example,
may resist the introduction or expansion of a lay health
worker programme if they perceive that the income or sta-
tus of nurses might be affected [14,16]. Civil society
organisations, too, may actively oppose changes that
would reduce prescription drug use among consumers,
particularly for life-sustaining drugs, and drugs that are
important in treating chronic conditions [14,17]. Such
changes could include the introduction of caps (i.e. con-
sumers are reimbursed up to a set maximum number of
prescriptions), co-insurance (i.e. consumers pay a per-
centage of the price of the prescription drug), and co-pay-
ments (i.e. consumers pay a fixed amount per prescription
drug).
Significantly, many on-the-ground realities and con-
straints can be addressed over time. Nurse practitioner
training programmes, for example, can be scaled up and
donors can subsidise the cost of an expensive drug like
ACT. Similarly, governments can improve the quality of
routinely collected data, and healthcare provider associa-
tions and civil society organisations can become engaged
in a series of negotiations or dialogues.
3. Are there important differences in health system 
arrangements that may mean an option could not work in 
the same way?
If the studies included in a systematic review were con-
ducted in settings with largely similar health system
arrangements to the setting where the findings may be
applied, particularly those that might substantially alter
the potential impacts of an option, policymakers might
reasonably expect similar relative effectiveness in their set-
ting. Deciding whether health system arrangements might
alter an option's impacts requires an understanding of
how and why an option might work. Within a systematic
review, policymakers may find both a framework and
research evidence that will identify those factors essential
for an option to work - or that might modify its impacts.
Policymakers may also find a summary of those features
of the settings in which studies were conducted that might
modify the impacts of an option.
If a systematic review does not provide the information
necessary to determine whether particular health system
arrangements might result in an option not working in
the same way, policymakers could look for:
￿ Policy analytic articles or narrative reviews incorporating
helpful frameworks that could be used to identify factors
that might modify the impacts of an option, and
￿ Detailed descriptions of the health system arrange-
ments, specifically those that might substantially alter the
potential impacts of an option, in the settings where the
studies were conducted
The European Observatory on Health Systems and Poli-
cies publishes, and periodically updates, profiles of the
health systems of a large number of middle- and high-
income countries. These 'Health in Transition' (HiT) pro-
files can be found online http://www.euro.who.int/
observatory/hits/20020525_1 and downloaded free of
charge. The Health Policy Monitor provides a searchable
online database of key health system features in some of
the same countries http://www.hpm.org/en/
Search_for_Reforms/Search.html. Many World Health
Organization regional offices also provide profiles of the
health systems of countries in their region (e.g. http://
www.searo.who.int/EN/Section313/
Section1515_6038.htm).
Policymakers in a setting with very different health system
arrangements, specifically arrangements that appear sig-
nificant in determining whether an option will function
in the same way, should be cautious about assuming that
comparable relative effectiveness could be achieved. For
example, in a review of reference drug pricing [9], six of
the ten studies were conducted amongst older people/Health Research Policy and Systems 2009, 7(Suppl 1):S9 http://www.health-policy-systems.com/content/7/S1/S9
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pensioners in British Columbia, Canada. Policymakers in
other settings may well conclude that they will not be able
to achieve comparable impacts to those seen in the Cana-
dian example if they have any of the following issues
within their own health system arrangements:
￿ Inadequate incentives for consumers, healthcare provid-
ers, pharmacists and pharmaceutical companies to com-
ply with the reference drug price system, and
￿ An electronic processing system that lacks the capacity to
realise the low administration costs associated with iden-
tifying, prescribing and dispensing the reference drugs
and with handling exemptions
Similarly, other pricing policies examined in competitive
pharmaceutical markets may yield a different relative
effectiveness in markets with monopolies.
Unlike the possibility of associated change in on-the-
ground realities that we discussed in Question 2 earlier,
Table 1: An assessment of the local applicability of a systematic review about home care (from the perspective of a Canadian 
policymaker)
Policymakers assessing the applicability of a 2005 review of home care could apply the series of questions discussed earlier as follows [24]:
1. Were the studies included in the systematic review conducted in the same setting or were the findings consistent across settings or time 
periods?
• 22 studies were included in the review
 9 from the United Kingdom (UK)
 3 from Australia
 1 each from Italy, Norway, and the United States
 7 were not described in a way that identified the country in which the study was conducted
• Findings were not consistent across settings
• Two studies were published in 1978 while the others were published from 1992 onwards. Many did not specify a time period, making it difficult 
to support the contention that the findings were consistent over time periods
2. Are there important differences in on-the-ground realities and constraints that might substantially alter the feasibility and acceptability of an 
option?
• In Canada, nurses are in tremendous demand (particularly in hospitals) and many are not used to the scope of practice required in home care 
settings. This means that many nurses might not embrace career opportunities in home care settings
• In Canada, unlike in the UK where 9 of 13 identifiable studies were conducted, citizens differ in whether they have supplementary coverage 
permitting more intensive home care. This means that relatively more wealthy people may get access to home care than the less well off
• In Canada, unlike in the UK, home care recipients and their families may have to travel very long distances if they have to seek acute care. Some 
may therefore delay their discharge from hospital; others may suffer if a hospital transfer is difficult
• In Canada, nurses may face a drop in pay if they move from hospitals to the community. Many of them may therefore actively oppose a shift 
from hospital care to home care
• In Canada, there is even more of a separation between health and social services (at least outside the province of Quebec) than there is in the 
UK, which means that caregivers may face a greater burden that is not covered by social services
3. Are there important differences in health system arrangements that may mean an option could not work in the same way?
• In Canada, as suggested earlier, home care recipients and their families cannot rely on the same breadth of services available to those in the UK 
(at least outside the province of Quebec)
• In Canada, unlike in the UK, there is a governmental commitment to first-dollar coverage for hospital-based and physician-provided care but 
not for home care, which means that Canadian home care recipients and their families may face significant financial barriers to accessing home 
care
• In Canada, unlike in the UK, most Canadians are not 'attached' to a multi-disciplinary primary healthcare practice, and some Canadian home 
care recipients would not even have a regular primary healthcare provider
4. Are there important differences in the baseline conditions that might yield different absolute effects - even if relative effectiveness was the same?
• In Canada, home care is already well established for most types of care, which means that the benefits may be small in absolute terms, at least 
for those not facing financial barriers
5. What insights can be drawn about options, implementation, and monitoring and evaluation?
• In Canada, admission-avoidance schemes may be a relatively unknown option compared to well-established schemes, such as the early 
discharge of elderly medical patients, or patients following surgery, or care of terminally ill patients
The review has now been updated and divided into two separate reviews, one of which deals specifically with admission-avoidance schemes and 
would be particularly relevant to Canada [25].Health Research Policy and Systems 2009, 7(Suppl 1):S9 http://www.health-policy-systems.com/content/7/S1/S9
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there is less chance that health system arrangements could
be modified. Health system arrangements are difficult to
change and typically the rationale underpinning a change
would need to be more compelling than only the possibil-
ity that it would enhance the impact of a single option.
4. Are there important differences in the baseline 
conditions that might yield different absolute effects even 
if the relative effectiveness was the same?
If the studies included in a systematic review were con-
ducted in settings with largely similar baseline conditions
to those in which the findings may be applied, such as in
terms of a programme's or policy's coverage of the popu-
lation, policymakers might reasonably expect similar
absolute effects in their setting (provided the answer they
gave to Question 3 above led them to expect similar rela-
Table 2: An assessment of the local applicability of a systematic review on lay health worker interventions (from the perspective of a 
South African policymaker)
Policymakers assessing the applicability of a 2006 review of lay health worker (LHW) interventions for maternal and child health in primary and 
community healthcare could apply the following series of questions [26,27]:
1. Were the studies included in the systematic review conducted in the same setting or were the findings consistent across settings or time 
periods?
• 48 studies were included in the review
 25 from the Unites States (US)
 3 from the United Kingdom (UK)
 2 each from Brazil, South Africa and Tanzania
 1 each from Bangladesh, Canada, Ethiopia, Ghana, India, Ireland, Mexico, Nepal, New Zealand, Pakistan, Philippines, Thailand, Turkey, and 
Vietnam
• Findings were not always consistent across settings
• Most studies were published from 1995 onwards although one study was published in 1980. It is not clear from the review whether the findings 
were consistent over time periods
2. Are there important differences in on-the-ground realities and constraints that might substantially alter the feasibility and acceptability of an 
option?
• In South Africa, concerns have been expressed about the capacity of the health system and non-government organisations (NGOs) to provide 
clinical and managerial support for a very large scale-up of LHW programmes, particularly in currently under-resourced areas where, it could be 
argued, they are most needed. Capacity may be different from the high-income settings (US, UK) in which many of the studies were conducted
• In South Africa, there is some resistance among nurses, and within nursing professional associations, to extending the scope of practice of 
LHWs. This may restrict the range of tasks that LHWs are able to take on. While the acceptability of LHWs to consumers seems reasonable, 
based on observations from existing programmes, this is likely to vary across settings in the country and for different tasks 
(e.g. immunisation, breastfeeding promotion)
• In South Africa, most LHWs are currently involved in providing home-based care to people living with HIV/AIDS and treatment support to this 
group and to people with TB. It is not clear how feasible it would be to extend their roles to include the areas shown to be effective in the 
review (immunisation promotion, treatment of childhood infections, breastfeeding promotion). Furthermore, the LHW interventions shown to 
be effective in the review were focused on very specific health issues, such as the promotion of breastfeeding or immunisation uptake. Little 
evidence was identified regarding the effectiveness of more 'generalist' LHWs who are given responsibility for delivering a range of primary 
healthcare interventions
• In South Africa, norms and traditions regarding breastfeeding as well as differing baseline levels of breastfeeding and high rates of HIV/AIDS 
among mothers may alter the applicability of the review findings on LHWs for breastfeeding promotion
3. Are there important differences in health system arrangements that may mean an option could not work in the same way?
• In South Africa, LHWs are not licensed to dispense antibiotics for the treatment of acute respiratory infections in children or to dispense anti-
malarial drugs. It may therefore be difficult in the short- to medium-term to extend their scope of practice in this way, even if shown to be 
effective in a review
• In South Africa, most LHWs are employed by NGOs, who receive funding from the government for the LHWs' salaries. It is not clear how 
secure this funding mechanism is
4. Are there important differences in the baseline conditions that might yield different absolute effects - even if relative effectiveness were the same?
• Baseline immunisation rates may be lower in South Africa than in some of the settings where the studies on LHWs for immunisation were 
conducted (Ireland, USA). Higher absolute effects might therefore be anticipated in South Africa
5. What insights can be drawn about options, implementation, and monitoring and evaluation?
• Most of the LHW interventions shown to be effective were focused on single tasks. The effectiveness of 'generalist' LHWs who deliver a range 
of primary healthcare interventions needs evaluation.Health Research Policy and Systems 2009, 7(Suppl 1):S9 http://www.health-policy-systems.com/content/7/S1/S9
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tive effectiveness). Policymakers will often be able to find
information about baseline conditions within systematic
reviews in a section titled 'Characteristics of included
studies'. Alternatively, they may have to retrieve the origi-
nal studies included in the review in the hope that base-
line conditions were better described in them.
Policymakers will typically be able to find local evidence
about baseline conditions in their own setting. (Article 11
in this series addresses how to find and use local evidence
[18].)
Policymakers in a setting with different  baseline condi-
tions may expect different absolute impacts. The absolute
impact of audit and feedback, for example, is likely to be
larger than in instances where the baseline compliance to
recommended practice is low [19]. Similarly, the absolute
impact of a pay-for-performance initiative may be larger
in low- and middle-income countries (where small finan-
cial incentives may be larger relative to wages) than in
high-income countries [20].
This question highlighting the link between baseline con-
ditions and absolute effects is also highly relevant in clin-
ical settings in which the relative effectiveness of a clinical
intervention is often the same across patients but where
patients' baseline risks may vary quite dramatically
[21,22]. The question is also highly relevant in public
health settings where immunisation programmes, for
example, might be introduced in countries with very dif-
ferent baseline conditions. Article 16 of this series dis-
cusses the use of balance sheets to summarise important
impacts and provides further detail about relative effec-
tiveness and absolute impacts [23].
5. What insights can be drawn about options, 
implementation, and monitoring and evaluation?
Even if the findings from systematic reviews are not
directly applicable to a given setting, important lessons
can still be drawn. Policymakers may be provided with an
idea for an option that they might otherwise not have con-
sidered. They may also gain insight into how options have
been implemented in other settings. And they may be able
to draw directly on the systematic review itself in develop-
ing a monitoring and evaluation plan. Policymakers may
learn, for example, about a new approach to supporting
team-based care, the importance of engaging both mid-
level managers and front-line nurses in the implementa-
tion of an option, and what types of outputs and out-
comes they should track as they monitor and evaluate the
implementation of a selected option.
Table 1 and Table 2 provide examples of an assessment of
the applicability of a systematic review.
Conclusion
Assessments of the applicability of the findings of a sys-
tematic review can take a lot of time to do well. Such
assessments are critical, however, when an option is being
proposed on the basis of a relevant high-quality system-
atic review. Policymakers and other stakeholders need to
know whether they can expect similar findings in their
own settings. Unlike an assessment of the quality of a
review, which can often be delegated to researchers, a
local applicability assessment must be done by individu-
als with a very good understanding of on-the-ground real-
ities and constraints, health system arrangements, and the
baseline conditions in the specific setting. The assessment
of local applicability is a domain in which policymakers
and those who support them need to be actively engaged.
Resources
Useful documents and further reading
- Dans AL, Dans LF, Guyatt GH: Applying results to indi-
vidual patients. In Users' Guides to the Medical Literature. A
Manual for Evidence-Based Clinical Practice. Edited by Guy-
att GH, Rennie D, Meade MO, Cook DJ. New York, USA:
McGraw Hill; 2008.
- Haynes RB: Can it work? Does it work? Is it worth it?:
The testing of healthcare interventions is evolving,
http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC1116525/. BMJ 1999, 1999: 652-653.
Links to websites
- SUPPORT Collaboration: http://www.support-collabo
ration.org - Example of a source of policymaker-friendly
summaries of systematic reviews that provides an assess-
ment of the applicability of the findings of each review (in
this case to low- and middle-income countries), and that
highlights the factors that policymakers need to bear in
mind when assessing the applicability of the findings to
their own setting.
- European Observatory on Health Systems and Policies:
http://www.euro.who.int/observatory/hits/20020525_1 -
Example of a source of (Health in Transition) profiles of
the health systems of a large number of middle- and high-
income countries.
- Health Policy Monitor: http://www.hpm.org/en/
Search_for_Reforms/Search.html - Searchable online
database of key health system features in a number of
middle- and high-income countries.
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